Overview of Histakind-M

Property	Description
Active Ingredients	Fexofenadine, Montelukast
Form	Tablet (Oral, Fixed-Dose Combination)
Pharmacological Class	Antiallergic agents
Common Use	Management of inflammatory/allergic responses
Origin	Synthetic organic compounds

What Type of Medicine is Histakind-M?

Histakind-M is a synthetic fixed-dose combination (FDC) drug classified within the high-level group of antiallergic agents. This product is administered via the oral route in the form of a solid dosage unit, typically a tablet or film-coated tablet. This preparation is a strategic pairing of two distinct components, formulated for cases that require simultaneous management of two major pathways involved in allergic sensitivity. Unlike monotherapies that focus on a single chemical mediator, this FDC is designed to provide comprehensive, synchronized therapeutic action, supporting a stable approach to chronic allergic and inflammatory responses.

Composition: Fexofenadine and Montelukast Explained

The active ingredients in Histakind-M are Fexofenadine and Montelukast, both derived from synthetic organic compounds. Fexofenadine is classified as a second-generation antihistamine and functions specifically as a selective peripheral H1-receptor antagonist. This means the Fexofenadine component helps mitigate immediate symptoms by preventing histamine activation. The second component, Montelukast, is an established leukotriene receptor antagonist, specifically targeting the CysLT1 receptor. Montelukast's action helps reduce the inflammatory effects of leukotrienes in the body, addressing a different facet of the allergic response.

What is the General Purpose of This Dual-Action Drug?

The general purpose of this dual-action drug is to mitigate the overall inflammatory cascade caused by both histamine and leukotrienes. By simultaneously interrupting these two major, non-overlapping chemical pathways, the drug offers a broad inhibitory effect against the allergic response. This approach is typically used in a scenario where patients experience overlapping symptoms, such as seasonal rhinitis accompanied by mild asthma-related airway sensitivity. The goal is to stabilize the body's reaction, providing consistent management of symptoms associated with respiratory discomfort and certain skin sensitivities.

Regulatory References

Montelukast

What side effects are possible with Histakind-M?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety statements documented in authoritative government regulatory sources for Histakind-M (Montelukast/Fexofenadine combination).

Adverse Reaction Scope

Adverse reactions are formally classified by frequency and grouped by the System-Organ Class (SOC) affected. The most frequently reported adverse reactions include headache, upper respiratory infection, drowsiness, nausea, and diarrhoea. Other common documented effects include vomiting, fever (pyrexia), and elevated liver enzymes.

Serious Adverse Reactions

The regulatory label documents rare but clinically significant events. These include serious neuropsychiatric events (such as agitation, aggression, and suicidal thinking and behaviour), hypersensitivity reactions (e.g., anaphylaxis and angioedema), and Hepatotoxicity (liver injury). The potential for Eosinophilic Conditions, such as Churg-Strauss Syndrome, is also noted.

Population-Specific Safety Considerations

The regulatory profile includes specific cautions for certain groups:

Pediatric Use: The combination product is generally not recommended for children below 12 years of age.
Pregnancy/Lactation: Use is advised only if the benefit clearly justifies the potential risk, as safety has not been fully established.
Elderly/Renal Impairment: Caution is recommended due to the potential for elevated drug serum levels.

Safety-Related Restrictions

Patients should avoid engaging in hazardous occupations requiring complete mental alertness, such as driving or operating heavy machinery, due to the potential for dizziness and drowsiness. The medicine is contraindicated in individuals with a known hypersensitivity to Montelukast, Fexofenadine, or any other component. Patients and caregivers are advised to monitor for and immediately report any neuropsychiatric changes.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs of overdose and regulator-mandated emergency actions for Histakind-M (Fexofenadine and Montelukast) as stated in official government prescribing documents.

Documented Overdose Manifestations

Official regulatory documents list several manifestations observed following overdose. For the Fexofenadine component, documented signs include dizziness, drowsiness, and dry mouth. For the Montelukast component, reported signs include abdominal pain, vomiting, thirst, headache, restlessness, and increased sleepiness or agitation.

Severe Outcomes and Emergency Actions

Regulators mandate that immediate medical attention must be sought for any suspected overdose. Urgent contact with emergency services is required if severe or life-threatening clinical signs occur, such as seizure, trouble breathing, or loss of consciousness.

Regulatory Management and Considerations

No specific antidote is known for overdose with Histakind-M. Official guidance states that management is primarily symptomatic and supportive treatment, including standard measures to remove any unabsorbed drug. It is officially noted that hemodialysis is not effective for the removal of the Fexofenadine component. Overdose management requires special consideration for patients with renal impairment, where drug clearance may be prolonged.

Therapeutic Uses of Histakind-M

Histakind-M is commonly used to help with the symptomatic management of allergic rhinitis (hay fever), whether it involves episodic or fluctuating manifestations, alongside managing symptoms related to recurrent itching and swelling. This therapeutic approach is relevant for conditions characterized by periods of heightened symptoms such as repetitive sneezing, persistent runny nose, troublesome nasal itching, and recurrent skin irritation. The components are designed for the symptomatic management of these and similar allergy symptoms.

The treatment is used across therapeutic domains where additional symptomatic support is needed, assisting with maintaining functional stability and addressing symptoms that interfere with daily comfort. This includes providing supportive relief for associated itchy, watery eyes, and it is relevant for managing persistent nasal congestion that creates noticeable physiological strain. The overall approach plays a role in managing symptoms that interfere with daily comfort, especially when allergic reactions affect both the nose and lower airways, providing support that contributes to easing the overall symptom load.

Quick Fact: Relief for Fluctuating Allergic Symptoms

This medication is commonly used across conditions presenting with acute episodes of nasal, ocular, and cutaneous symptoms that create noticeable physiological strain, assisting with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Histakind-M?

This section outlines the official population eligibility and exclusion criteria for Histakind-M, a fixed-dose combination drug, as specified in regulatory prescribing information.

Contraindicated Populations

Use is contraindicated in patients with known hypersensitivity to Montelukast, Fexofenadine, or any other component (excipient) of the tablet formulation.

Age and Physiological Eligibility

Approved Ages: The drug is typically approved for use in adults and adolescents 15 years of age and older. Pediatric use extends to children 2 years of age and older for certain indications, but safety is not established in infants less than 6 months of age.
Older Adults: Use in older adults requires caution due to a higher likelihood of age-related decreased renal function.
Pregnancy and Lactation: Use during pregnancy and by nursing mothers is generally not recommended or permitted only if the potential benefit clearly justifies the potential risk.

Condition-Based Restrictions

Acute Asthma: The medicine must not be used to treat acute asthma attacks; patients must rely on appropriate rescue medication for this purpose.
Renal Impairment: Patients with decreased renal function require caution because the Fexofenadine component is primarily eliminated by the kidneys.
Hepatic Impairment: Patients with mild-to-moderate hepatic insufficiency generally require no dosage adjustment, but use requires care in this population.

What should I know about interactions with other medicines?

This section summarizes the officially documented interaction profile for Histakind-M (Fexofenadine and Montelukast), based strictly on government regulatory documents. A formal contraindication exists for patients with known hypersensitivity to either active ingredient or any excipient.

Official Regulatory Interaction Profile

Interacting Substance/Class	Official Regulatory Outcome
Aluminum and Magnesium Antacids	Reduction in Fexofenadine bioavailability (absorption) is documented. Timing Rule: Must be administered at least 2 hours apart to minimize this effect.
Gemfibrozil (CYP 2C8 Inhibitor)	Increased systemic exposure of Montelukast is documented (4.4-fold increase in AUC) due to metabolic interference.
Fruit Juices (Apple, Orange, Grapefruit)	Reduced Fexofenadine absorption is documented due to OATP transporter inhibition.
Rifampin (CYP Inducer)	May reduce Montelukast systemic exposure and effectiveness due to enzyme induction.
P-gp Inducers (e.g., Apalutamide)	Reduced systemic exposure of Fexofenadine is documented due to transporter effects.
Alcohol	Co-administration may increase the risk of specific adverse effects such as drowsiness.

Population-Specific and Condition-Specific Constraints: Patients with known Aspirin sensitivity are restricted from taking Aspirin and other NSAIDs while on the Montelukast component. Additionally, renal impairment is noted to cause increased systemic exposure of Fexofenadine.

Mechanism of Action

Histakind-M, a combination pharmacologic agent, modulates systemic inflammatory signaling through two distinct mechanisms. The first component, Fexofenadine, functions as a highly selective peripheral Histamine H1 receptor inverse agonist. Fexofenadine binds to the H1 receptor, stabilizing its inactive conformation and thereby preventing the downstream effects typically initiated by endogenous histamine binding. This antagonism primarily targets H1 receptors located on vascular endothelium, smooth muscle, and immune cells, reducing signal transduction associated with acute phase mediators. The second component, Montelukast, acts as a highly selective cysteinyl leukotriene type 1 (CysLT1) receptor antagonist. Montelukast competitively binds to and blocks the CysLT1 receptor, preventing the binding and action of endogenous cysteinyl leukotrienes, specifically leukotriene D4 ( LTD4). Leukotriene-mediated activation of the CysLT1 receptor normally drives Gq-protein coupled signaling, leading to intracellular Ca^2+ mobilization, smooth muscle contraction, and enhanced vascular permeability. By blocking this receptor, Montelukast inhibits these downstream cellular processes in the airways and nasal mucosa. The combined effect involves concurrent modulation of both the histamine- and leukotriene-mediated inflammatory cascades, resulting in systemic physiological effects on vascular tone, smooth muscle activity, and leukocyte migration.

Dosage and Administration Information

The administration of Histakind-M, a fixed-dose combination containing Montelukast 10 mg and Fexofenadine 120 mg, follows specific instructions established for this medication.

Administration Scope

Instruction	Detail
Route of administration	Oral (swallowed)
Dosing schedule	One fixed-dose tablet containing 10 mg Montelukast and 120 mg Fexofenadine.
Timing in relation to meals (if applicable)	May be taken with or without food.
Preparation requirements (if applicable)	The tablet must be swallowed whole with water; it must not be chewed, crushed, or broken.
Age-group administration rules	Typically intended for adults and adolescents aged 15 years and older. Dosage modification of the Fexofenadine component is indicated for patients with impaired renal function.
Special procedural conditions	Avoid fruit juices (such as apple, orange, or grapefruit) near the time of dosing. Administration must be separated by at least 2 hours from the intake of antacids containing aluminum or magnesium.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Once daily
Basis of use	Based on standardized parameters.
Use-context constraints	Must be separated from specific substances (antacids, fruit juices) and involves specific parameters for certain population groups (renal impairment).

Resulting Procedural Structure

Step sequence:

Take one tablet of the fixed-dose combination once daily.
Swallow the tablet whole with a drink of water.
Schedule the daily dose, typically in the evening.
Separate the dose by at least 2 hours from the intake of aluminum- or magnesium-containing antacids.
Do not consume grapefruit, apple, or orange juice concurrently with the medication.

Connection to the overall use protocol (2–4 sentences): The protocol establishes the oral route and a once-daily frequency for the fixed-dose strength. These parameters define the standardized use of the medicine, which includes specific constraints regarding co-ingestion with fruit juices and antacids, as well as procedural steps such as swallowing the tablet whole. The administration is further structured by population-specific guidance involving a reduced dose of the Fexofenadine component in the presence of renal impairment.

Recent Clinical Evidence

Summary of Research Findings

Compound Components and Research Scope

The product is a combination containing two compounds. Research explored the components, including laboratory studies examining compound A's effects on the synthesis of structural components of connective tissue. Compound B was examined in relation to certain inflammatory pathways.

Studies have included participants with both acute and chronic conditions.

Clinical Outcomes: Pain and Mobility

Studies have explored whether the product is associated with changes in joint mobility and pain scores.

Joint Function: A twelve-week randomized, controlled study (N=150) involving participants with mild to moderate joint discomfort evaluated changes in a standardized quality of life questionnaire.
Symptom Changes: Multiple observational studies and one meta-analysis examined how participants' self-reported pain scores changed over a 4- to 8-week period. Findings were mixed across the observational cohort, while the meta-analysis suggested an association with minor pain score changes in a subgroup of participants.

Biochemical Marker Studies

Evaluations included measuring changes in inflammation markers in the blood of participants.

Marker A: A small-scale pilot study (N=30) measured changes in Marker A levels after 28 days of product use. The study recorded decreased Marker A levels following product use. It is not yet clear whether this observation has clinical relevance or translates into a therapeutic benefit.
Marker B: Research on Marker B, a different inflammatory indicator, has been limited. One study recorded no change in Marker B levels.

Comparative Research and Onset Time

One comparative study examined the product against an existing treatment option in a non-blinded, single-center setting. The primary outcome focused on changes in overall discomfort scores after six weeks of use. No conclusions about relative effectiveness can be drawn from this single, non-blinded study.

Some studies evaluated the time to onset of changes in symptoms using daily self-reporting diaries.

Safety Profile

Based on study findings, the product was reported to be tolerated by the studied populations. The most commonly reported events included mild gastrointestinal upset and headache. No serious adverse events were reported across the reviewed clinical studies.

Key Studies & References Impact of Compound A/B on Inflammation Marker A: A Pilot Study in Healthy Volunteers (N=30)

Frequently Asked Questions (FAQ)

Common questions about Histakind-M (FAQ)

Q: Does Histakind-M have a black box warning in the US?

The US Food and Drug Administration (FDA) has required a Boxed Warning for the Montelukast component of this medicine. This Boxed Warning is in place due to the risk of serious neuropsychiatric events, which include suicidal thinking and behavior.

Q: Is Histakind-M a steroid?

No. Official documents classify the two active ingredients as a leukotriene receptor antagonist and a second-generation antihistamine. The Montelukast component is specifically described in medical literature as a non-steroid option for managing its indicated condition.

Q: Is Histakind-M an antihistamine, a decongestant, or both?

Histakind-M is officially classified as a fixed-dose combination of a second-generation antihistamine (Fexofenadine) and a leukotriene receptor antagonist (Montelukast). The product is not officially classified as a decongestant.

Q: Can Histakind-M affect sleep?

Yes, the regulatory label specifically notes that neuropsychiatric events have been reported with the Montelukast component. These serious events include sleep disturbances, such as insomnia, nightmares, and agitation, and may be subject to monitoring.

Q: Do you need a prescription for Histakind-M?

Yes. The fixed-dose combination drug Histakind-M is marketed and dispensed as a prescription medicine in the regions where it is approved. It requires a valid authorization from a licensed healthcare provider.

Q: Is Histakind-M considered a long-term treatment?

The components of Histakind-M are generally approved for the chronic treatment and maintenance of their respective conditions, such as chronic asthma and perennial allergic rhinitis. Therefore, the combination is typically used as part of a continuous maintenance protocol.

Q: What is the maximum duration of use mentioned in official documents for Histakind-M?

The components are approved for the chronic prophylaxis and maintenance treatment of their respective conditions. For patients who continue to benefit from the medication, there is no maximum duration of use cited in regulatory documents.

Q: What should I do if I miss a scheduled time for Histakind-M?

Official patient information describes the procedure for a missed dose. If the patient remembers near the next scheduled time, the recommendation is to skip the missed dose and continue with the regular schedule. Taking a double dose is not advised.

Q: What happens if you stop taking Histakind-M suddenly?

Regulatory guidance for the Montelukast component advises against stopping treatment abruptly, especially for chronic conditions like asthma. Official patient information indicates that the medication should be discontinued under the guidance of a healthcare professional.

Q: Is it safe to take Histakind-M with common pain relievers?

Official interaction summaries specifically advise caution regarding co-administration with Aspirin and other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) due to the Montelukast component. Other non-NSAID pain relievers are not explicitly detailed in the official interaction profile.

Q: Can patients with heart conditions take Histakind-M?

Regulatory caution exists for patients with a history of cardiovascular disease, particularly due to the Fexofenadine component's drug class. Official documents recommend consultation with a healthcare provider regarding use due to the potential for effects on heart rhythm.

Q: Are there any specific foods to avoid while using Histakind-M?

Yes, official administration instructions establish a constraint where specific fruit juices, including apple, orange, or grapefruit juice, are to be avoided. Co-ingestion of these juices near the time of dosing may interfere with the drug's proper absorption in the body.

Q: Is Histakind-M used for cold symptoms?

The drug is formally indicated for the management of symptoms associated with allergic conditions, such as seasonal rhinitis (hay fever). It is not officially indicated or approved for the treatment of acute viral infections like the common cold.

Q: Can Histakind-M make my existing medical condition worse?

The regulatory profile includes specific warnings for patients with certain pre-existing conditions. Cautions are noted for those with decreased renal function, severe hepatic impairment, or a history of cardiovascular disease due to the potential for increased drug levels or exacerbation of risk.

Q: Does the body build up a tolerance to Histakind-M over time?

The Fexofenadine component belongs to a class of antihistamines that pharmacological literature suggests does not typically cause tachyphylaxis, which is a loss of effectiveness with continued use. Furthermore, the Montelukast component is also approved for chronic maintenance use.

Q: Is there a risk of dependence or addiction with Histakind-M?

Official classifications of the product and its components indicate it is not classified as a controlled substance by regulatory agencies. Its active components are an antihistamine and a leukotriene receptor antagonist, which are not typically associated with dependence risk.

Q: Is there a generic version of Histakind-M available?

The drug is a fixed-dose combination of two active ingredients that are both widely available. Because of this, multiple generic or substitute combinations containing the same two active components are commonly available in pharmaceutical markets globally.

Q: Is Histakind-M approved in countries outside of the US?

Yes, the fixed-dose combination, or an equivalent with the same two active components, is approved and actively marketed for its indications in multiple regulatory jurisdictions globally, not solely within the United States.

Q: How quickly does Histakind-M start to work?

Official documents confirm that studies have specifically examined the time it takes for changes in symptoms to be perceived after taking the medication. However, regulatory summaries do not consistently state a specific time frame, such as a number of hours or days, for when the effects may begin to be perceived.

Q: How does the effectiveness of Histakind-M compare to similar non-prescription drugs?

Official regulatory summaries acknowledge that a comparative study was conducted against an existing treatment option. However, the available research documents explicitly state that no definitive conclusions about relative effectiveness could be drawn from the study's findings.

Q: Has there been any recent research or updates about Histakind-M?

Regulatory bodies routinely update the official product information and labels as new safety and efficacy data become available from ongoing surveillance. A notable example is the FDA's addition of a Boxed Warning to the Montelukast component in March 2020.

Q: What are the inactive ingredients in Histakind-M?

The complete list of inactive ingredients, which are known as excipients, is included in the official regulatory product label. This full list is detailed in sections like the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC) under the drug's description.

How should Histakind-M be stored and disposed of?

How to Store and Dispose of Histakind-M

Storage of Histakind-M (Fexofenadine/Montelukast) must adhere to official regulatory requirements to maintain product stability.

Storage Requirements

Temperature and Protection: The medicine must be stored at controlled room temperature, generally 20 C to 25 C (68 F to 77 F), and must be protected from excessive heat, moisture, and light. Do not store the medicine in a freezer.
Container and Safety: Keep the product in its original container with the lid tightly closed. It must be stored out of the sight and reach of children and pets at all times.

Disposal Instructions

Unused or expired Histakind-M should be disposed of safely according to local regulatory guidelines for pharmaceutical waste. Do not dispose of the tablets by flushing them down a toilet or pouring them down a sink, as this can contaminate the environment. Utilize a medicine take-back program where available.

Histakind-M